SCHEMBL417504

SCHEMBL417504

CC1(C)OCCn2c1nc(C(=O)NCc1ccc(F)cc1)c(O)c2=O

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.51
CYP2C9 P11712 1/20 0.51
KCNE1 P15382 1/20 0.45
CCR1 P32246 1/20 0.45
KCNQ1 P51787 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
CALCA P06881 1/20 0.42
GAA P10253 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ERCC1 P07992 1/20 0.41
FEN1 P39748 1/20 0.41
ERCC4 Q92889 1/20 0.41
LIPG Q9Y5X9 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13917379 0.95 KCNH2 (0.54) KCNH2CYP2C9KCNE1CCR1KCNQ1
SCHEMBL13917626 0.92 KCNH2 (0.42) KCNH2CYP2C9KCNE1CCR1KCNQ1
SCHEMBL13917595 0.91 TP53 (0.43) KCNH2CYP2C9KCNE1CCR1KCNQ1
SCHEMBL13917363 0.90 TP53 (0.43) KCNH2CYP2C9SMN1; SMN2GAAMEN1
SCHEMBL13917621 0.90 KCNH2 (0.41) KCNH2CYP2C9KCNE1CCR1KCNQ1
SCHEMBL13917462 0.90 CALCA (0.43) KCNH2CYP2C9KCNE1CCR1KCNQ1
SCHEMBL13917571 0.90 ALDH1A1 (0.44) KCNH2CYP2C9CALCAMEN1KMT2A
SCHEMBL13917365 0.90 KCNH2 (0.41) KCNH2CYP2C9KCNE1CCR1KCNQ1
SCHEMBL13917457 0.89 KCNH2 (0.41) KCNH2CYP2C9KCNE1CCR1KCNQ1
SCHEMBL13917353 0.89 AKR1B10 (0.41) KCNH2CYP2C9KCNE1CCR1KCNQ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012095388-A2 COMPOUNDS FOR TREATMENT OF FELINE LEUKEMIA IN FELIDAE Universität Zürich (CH) 2012-07-19 WO claimed
US-7491819-B1 N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor BRISTOL-MYERS SQUIBB COMPANY (US) 2009-02-17 US claimed
EP-1749011-B1 BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2008-10-29 EP claimed
WO-2007064502-A1 FORMS OF N-[(4-FLUOROPHENYL)METHYL]-4,6,7,9-TETRAHYDRO-3-HYDROXY-9,9-DIMETHYL-4-OXO-PYRIMIDO[2,1-C][1,4]OXAZINE-2-CARBOXAMIDE BRISTOL-MYERS SQUIBB COMPANY (US) 2007-06-07 WO claimed
US-7176196-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-13 US claimed
EP-1749011-A1 BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-02-07 EP claimed
WO-2005118593-A1 BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-12-15 WO claimed
US-20050267105-A1 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-12-01 US claimed
US-20130338141-A1 HIV INTEGRASE INHIBITORS ISAACS RICHARD C (US) 2013-12-19 US disclosed
US-8513234-B2 HIV integrase inhibitors MERCK SHARP & DOHME CORP. (US) 2013-08-20 US disclosed
WO-2012095388-A2 COMPOUNDS FOR TREATMENT OF FELINE LEUKEMIA IN FELIDAE Universität Zürich (CH) 2012-07-19 WO disclosed
WO-2012095388-A2 COMPOUNDS FOR TREATMENT OF FELINE LEUKEMIA IN FELIDAE Universität Zürich (CH) 2012-07-19 WO disclosed
US-20120022045-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS VENKATRAMAN SHANKAR (US) 2012-01-26 US disclosed
EP-2349276-A2 HIV INTEGRASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2011-08-03 EP disclosed
US-7176196-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-13 US disclosed
US-7176196-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-13 US disclosed
US-7157447-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-02 US disclosed
US-7157447-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-02 US disclosed
US-7157447-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-02 US disclosed
US-20060199956-A1 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338141-A1 HIV INTEGRASE INHIBITORS POLB, CCNB1, POLR2A KCNH2 3072/4885CYP2C9 896/4885KCNE1 3058/4885
US-20120022045-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS CCND3, CDK3, CDK2 KCNH2 2502/4885CYP2C9 1960/4885KCNE1 2089/4885
US-20060199956-A1 Bicyclic heterocycles as HIV integrase inhibitors CCNI, TYMP, IMPDH1 KCNH2 2366/4885CYP2C9 301/4885KCNE1 3260/4885
US-20050267105-A1 Bicyclic heterocycles as HIV integrase inhibitors CCNI, TYMP, IMPDH1 KCNH2 2366/4885CYP2C9 301/4885KCNE1 3260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.